Login to Your Account

NeuroVive Entering Chinese Market with Sihuan Alliance

By Nuala Moran
Staff Writer

Wednesday, November 28, 2012
LONDON – NeuroVive Pharmaceutical AB signed a deal for the development of its two lead mitochondria-sparing programs in China to add to a similar agreement in Europe that should see the two drugs through to commercialization in both markets.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription